

Professor Jeremy K. Nicholson
Head of the Department of Surgery and Cancer
Director, MRC-NIHR National Phenome Centre
Faculty of Medicine, Imperial College London



Professor Nicholson obtained his PhD in Biochemistry from St Thomas's Hospital Medical School, London University (1980) and after several London University academic appointments in Pharmacology and Chemistry (Full Professor, 1992), he became Head of Biological Chemistry at Imperial College London (1998) and then Head of the Department of Surgery and Cancer (2009). He is the Director of the MRC-NIHR National Phenome Centre and the Imperial-Institute of Cancer Research joint Centre for Systems Oncology. Professor Nicholson has authored over 500 peer-reviewed papers on molecular aspects of complex system failure and systems medicine. He leads the Imperial Biomedical Research Centre and AHSC research programmes in Stratified Medicine for optimising translational medicine for patient safety and healthcare delivery. His research has been recognised by awards such as: The Royal Society of Chemistry Silver (1992) and Gold (1997) Medals for Analytical Science and Analytical Chemistry respectively; The UK Chromatographic Society Silver Jubilee Medal (1994); Pfizer Prize for Chemical and Medicinal Technology (2002); RSC medal for Chemical Biology (2003); The RSC Interdisciplinary Prize (2008); The RSC Theophilus Redwood Lectureship (2008); The Pfizer Global Research Prize for Chemistry (2006); The NIH Stars in Cancer and Nutrition Distinguished Lecturer (2010) and The Semelweiss-Budapest Prize for Biomedicine (2010). He is a Fellow of The Royal College of Pathologists, The Royal Society of Chemistry, The Society of Biology and The British Toxicological Society. In 2010 he was elected Fellow of The UK Academy of Medical Sciences. In 2012 he was elected as the first Honorary Fellow of the Metabolomics Society and in 2013 an Honorary Member of the US Society of Toxicology. He currently holds honorary professorships at 7 Universities including two Institutes of the Chinese Academy of Sciences and is a founder director of Metabometrix, an Imperial College spin-off company (founded 2001) specializing in molecular phenotyping, clinical diagnostics and toxicological screening.